One pharmacist. One knowledge-based company. One year. $2.7 million savings.April 20, 2018
One pharmacist evaluating specialty drug claims using integrated medical and pharmacy claims and PA data can identify enough savings opportunities to achieve a 9:1 ROI
In this study, one managed care pharmacist armed with advance analytics worked through integrated medical and pharmacy benefit claims records. By collaborating with the Blue Plan insurer case management team, the pharmacist was able to optimize drug therapy. This resulted in substantial drug savings.
After reviewing approximately 1,500 member files, 365 were identified as having an actionable opportunity. The pharmacist reviewed the drug therapy regimens of selected high-drug-cost identified members. The regimens were evaluated to ensure appropriate use, identify suspicious utilization, and discover savings opportunities. Advanced analytics combed through millions of member files to zero in on 1,500 members to assess. Of the 365, 20 resulted in validated savings.
Savings opportunities were classified as:
- Changes in drug dosing units
- Therapy changes
- PA approval process changes
- FWA recovery and future claims avoidance
While 20 may sound like a small number, the high-value opportunities and PA process changes added up quickly, to a total of $2.7 million.
For example, a change to the detailing process to ensure correct number of fills in hepatitis C claims affected 28 members and added up to $1 million in savings. Package size optimization for seven members using secukinumab Prime calls another win for carve-in pharmacy benefits; it’s just better than carve-outsaved $327,000.
After subtracting salary and administrative costs of $300,000, final savings totaled $2.4 million, giving a return on investment of 9:1. All savings were validated by claims or by the health plan.
March 30, 2023
Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs
If you have a chronic condition, your pharmacy may notify you advance of…
March 28, 2023
Biosimilars are at the door, Part 3
News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…
March 27, 2023
Specialty Drug Pipeline Update: March 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…